NIH launches database to track neurological symptoms associated with COVID19Knowledge
A new study to track neurological symptoms associated with COVID19 has been launched this month in the United States. The National Institute of Health will support the NeuroCOVID Project through a dual-purpose database: the NeuroDatabank and the NeuroBioBank.
There are a variety of neurological symptoms being experienced by people with COVID19, many of which continue to affect people long after the infection has passed, known as Long-COVID. These symptoms include, but are not limited to, headaches, fatigue, cognitive difficulties, stroke, pain, and sleep disorders.
Funded by the National Institute of Neurological Disorders and Stroke, the study has been initiated at NYU Langone Health, and seeks to both document and study the neurological complications caused by COVID19.
The new database will collect information in two forms. The NeuroDatabank will gather patient information on any person of any age who has a confirmed COVID-19 infection in the United States. The NeuroBioBank will collate biological samples, including blood, plasma, cerebrospinal fluid, and tissue, from patients who both have COVID-19 and experience neurological complications.
The NeuroCOVID project can be used by scientists for research studies on preventing, managing, and treating neurological complications associated with COVID-19. It is hoped that the database may provide insight into how COVID-19 affects the nervous system, and how likely it is that such complications will occur.